Enveda Raised $311 Million in Series E Funding
The biotech firm secured fresh capital to scale its AI-driven drug discovery platform and advance clinical trials.
Updated on Sept. 23, 2026 in Biotech
Live Poll
Do you believe AI-driven drug development will make medical treatments more affordable and effective?
Enveda has closed a $311 million Series E funding round, bringing the company total to $845 million in lifetime capital. The funding will support the acceleration of clinical programs and the expansion of the firm's AI-native drug discovery technology.
Why it matters
This capital injection enables Enveda to push its oral drug candidates into later-stage clinical development. It also provides the resources to scale the PRISM platform, which identifies biologically active molecules found in nature.
Enveda has generated 17 development candidates and currently manages three oral drug candidates in clinical trials. The company utilizes its proprietary PRISM platform to analyze natural molecules for potential medical applications.
The players
Enveda
A biotechnology company that uses an AI-native platform to discover and develop new drug candidates from natural sources.
Catalio Capital Management
A specialized investment firm that led the latest round of financing for Enveda.
The details
Led by Catalio Capital Management, the funding syndicate supports the further development of pipeline assets including ENV-294 for atopic dermatitis and ENV-308 for metabolic health. The firm continues to expand its catalog of discovery candidates beyond its current clinical trial portfolio.
Timeline
Two drug candidates reported positive early clinical results in 2026.
The Tech Race
This investment highlights the increasing reliance on AI-native drug discovery platforms to shorten development timelines in the pharmaceutical sector. By automating the search for active molecules, the company aims to displace traditional, slower research methodologies used by legacy drug manufacturers.
The firm's ongoing work on metabolic health treatments like ENV-308 could eventually offer new options for patients looking to prevent weight gain after GLP-1 therapy. These developments represent potential future therapeutic tools for addressing dermatological and metabolic conditions.
The takeaway
The move demonstrates a strong shift toward using data-intensive AI models to identify natural compounds for drug development. Investors are increasingly backing platforms that can turn biological data into actionable, patentable clinical candidates.
Further reading
For more on the current industry landscape, visit the Biotech section.
Live Poll
Do you believe AI-driven drug development will make medical treatments more affordable and effective?
